Results of a phase 3 clinical trial testing Orencia for the treatment of psoriatic arthritis were presented at the American College of Rheumatology ACR annual meeting in November According to an abstract from the ACR meeting, after 24 weeks, about 39 percent of people who had been taking Orencia experienced a 20 percent improvement in their condition, or ACR About 22 percent of people on the placebo achieved ACR20 in the same amount of time.
We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy. Helpline Back To Results. Orencia is manufactured by Bristol-Myers Squibb. Author National Psoriasis Foundation. News Analysis Analysis Comment Projects.
Join Our Newsletter - Get important industry news and analysis sent to your inbox — sign up to our e-Newsletter here. Powered by. We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Continue Learn more.
0コメント